Parkman Healthcare Partners LLC — 13F Portfolio

Parkman Healthcare Partners LLC is a healthcare-focused investment management firm headquartered in New York, New York, operating as a specialist hedge fund dedicated exclusively to the healthcare sector. The firm has established itself within the alternative investment landscape as a domain expert, applying deep fundamental research and industry expertise to identify investment opportunities across biotechnology, pharmaceuticals, medical devices, healthcare services, and related subsectors. Filing with the SEC under CIK #0001777015, Parkman Healthcare Partners maintains quarterly 13F disclosures documenting its long U.S. equity positions within its area of specialization. The firm operates under the leadership of Justin Ferayorni, who serves as Founder and Chief Investment Officer, bringing extensive healthcare investing experience to direct investment strategy and portfolio construction. Michael Cho contributes as Partner and Portfolio Manager, providing additional analytical depth and portfolio management capabilities. This focused leadership structure enables intensive fundamental research and specialized expertise development that would be difficult to replicate within generalist investment organizations. The platform's 13F archive enables researchers to examine the firm's disclosed healthcare positions across market cycles, providing insight into sector allocation evolution and subsector conviction patterns.

Parkman Healthcare Partners employs a sector-specialist investment strategy focused exclusively on healthcare equity opportunities. The firm's approach leverages deep fundamental research, scientific understanding, and industry expertise to identify mispriced securities across healthcare subsectors. This specialist orientation enables analytical depth and pattern recognition advantages relative to generalist investors covering healthcare as one component of diversified portfolios. 13F Portfolio Composition analysis reveals concentrated exposure across healthcare subsectors including biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services, and life sciences tools. The biotechnology emphasis reflects the sector's potential for substantial value creation through drug development milestones, clinical trial outcomes, and regulatory approvals. Pharmaceutical holdings capture opportunities in established drug companies navigating patent cliffs, pipeline developments, and strategic transactions. Medical device positions provide exposure to innovation in surgical technology, implantables, and diagnostic equipment. Sector Allocation History tracking demonstrates how the firm's subsector weightings have evolved in response to changing opportunity sets within healthcare. Biotechnology allocations may fluctuate based on valuation conditions, clinical catalysts, and risk appetite, while pharmaceutical and medical device weightings provide varying degrees of defensive characteristics. Top 10 Holdings Concentration metrics reveal conviction levels in highest-confidence ideas, with healthcare specialists often maintaining concentrated positions supported by deep fundamental research. As a hedge fund structure, the 13F filings represent only long U.S. equity positions, with short positions providing additional alpha sources and risk management remaining outside disclosure requirements. Portfolio turnover appears moderate to high, consistent with an event-driven component to the strategy where clinical catalysts, regulatory decisions, and M&A activity create tactical opportunities.

Parkman Healthcare Partners LLC represents a specialized New York-based hedge fund practicing dedicated healthcare sector investing with emphasis on biotechnology, pharmaceuticals, and medical devices. The firm's 13F filings document a concentrated healthcare equity approach leveraging deep fundamental research and industry expertise to identify mispriced opportunities across healthcare subsectors. The Ferayorni-Cho leadership team provides focused investment direction within a sector demanding substantial scientific and regulatory knowledge. The specialist model enables analytical depth advantages relative to generalist competitors while accepting sector concentration in exchange for domain expertise benefits. Annualized Return (CAGR) calculations applied to reconstructed long positions enable researchers to assess disclosed healthcare equity compounding behavior across varying biotech sentiment environments. Sharpe Ratio analysis provides risk-adjusted context, though healthcare sector volatility typically produces different risk-return profiles than diversified strategies. The platform's backtesting capabilities facilitate simulation of how disclosed positions would have performed relative to healthcare sector benchmarks. Simulated Growth Chart visualization offers perspective on how the disclosed healthcare portfolio has navigated the significant sector volatility experienced in recent years, including the biotechnology sector's meaningful correction and partial recovery. Key analytical question: How has the firm's subsector allocation between biotechnology, pharmaceuticals, and medical devices evolved in response to the substantial valuation compression in development-stage biotechnology since 2021, and does positioning suggest opportunistic accumulation during the correction or risk reduction in response to changed sector dynamics?

The risk architecture of Parkman Healthcare Partners' disclosed holdings reflects the distinctive characteristics of sector-specialist healthcare investing. The exclusive healthcare focus introduces sector concentration risk, as portfolio performance correlates strongly with healthcare industry dynamics including regulatory environment, drug pricing pressures, clinical trial outcomes, and biotech investor sentiment. Volatility Profile measurements derived from disclosed holdings typically exhibit elevated readings relative to diversified strategies, reflecting biotechnology's characteristic price volatility. Biotechnology subsector exposure introduces event-driven risk profiles where binary clinical trial outcomes and regulatory decisions can generate substantial single-position gains or losses. Max Drawdown Depth analysis across historical 13F filings illuminates how the portfolio has navigated healthcare-specific corrections including the 2021-2022 biotechnology sector decline that significantly impacted smaller-cap development-stage companies. The hedge fund structure implies short positions and hedging strategies that modify the risk profile beyond what 13F disclosures reveal. Sector specialists often employ pair trades, index hedges, or options strategies to manage systematic sector exposure while isolating security-specific alpha opportunities. Downside Capture Ratio examination of disclosed long positions provides partial insight into risk characteristics without capturing potential offsetting short book contributions. Healthcare investing requires navigation of regulatory, political, and reimbursement risks that introduce uncertainty beyond traditional fundamental analysis. The specialist team's industry expertise provides competitive advantage in assessing these sector-specific risks.